PREVALENCE OF SARCOPENIA AND ASSOCIATED FACTORS IN CHRONIC KIDNEY DISEASE: A CROSS-SECTIONAL STUDY
Main Article Content
Abstract
Background: Sarcopenia is common in CKD and portends adverse outcomes. Local data on correlates with age, BMI, kidney function and performance measures are limited. Objective: To estimate sarcopenia prevalence and analyze associated factors in CKD. Methods: Cross-sectional study of 101 adults with CKD. Variables included age, sex, CKD duration, BMI, albumin-to-creatinine ratio, eGFR categories (G1–G5), skeletal muscle index (SMI), appendicular skeletal muscle (ASM), percent body fat, handgrip strength and gait speed. Comparative and correlation analyses were performed. Results: Median age was 67 with 40.6% male. The eGFR G3b group was predominated and albuminuria A3 was most frequent. Sarcopenia prevalence was 33.7% with no sex difference. Sarcopenic patients were older (median age 70 vs. 65; p < 0,05) and had lower BMI ((21,7 ± 2,2 vs. 25,5 ± 2,9 kg/m²; p < 0,001). Handgrip strongly correlated with SMI (r = 0.694; p < 0.001) and inversely with gait time (r = −0.542; p < 0.001); SMI inversely correlated with gait time (r = −0.458; p < 0.001). Conclusion: About one-third of CKD patients had sarcopenia, associated with age, low BMI, and impaired physical performance, aligning with current international recommendations for systematic screening in CKD.
Article Details
Keywords
sarcopenia; CKD; SMI; handgrip; gait speed; eGFR; ACR.
References
2. Chatzipetrou V, Bégin M-J, Hars M, Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int. 2022;110(7):1–31. doi:10.1007/s00223-021-00898-1
3. Duarte MP, et al. Prevalence of sarcopenia in patients with chronic kidney disease: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2024; 15:501–512.
4. Zheng X, Ren X, Jiang M, Han L, Zhong C, et al. Association of sarcopenia with rapid kidney function decline and chronic kidney disease in adults with normal kidney function. Br J Nutr. 2024;131(5): 821–828. doi:10.1017/ S0007114523002313.
5. Yim J, Son N-H, Kim KM, Yoon D, Cho Y, Kyong T, Moon J-Y, Yi TI, Lee S-G, Park Y, Lee JJ, Kim K-A, Lee JE, Kim J-H. Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation. Front Med (Lausanne). 2022; 9:1021936. doi:10.3389/fmed.2022.1021936
6. Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16–31.
7. Chen LK, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2.
8. Lee Y-H, et al. Gait speed and handgrip strength as predictors of all-cause mortality in hemodialysis patients. BMC Nephrol. 2020; 21:166.